A Clinical Study Evaluating the Safety and Efficacy of CS-101 in Treating Subjects With β-thalassemia

Key Inclusion Criteria： * 6 to 35 years old(inclusive) male or female subjects at the time of informed consenting * Diagnosis of β-thalassemia, genotypes include but are not limited to β+β0，βEβ0，β0β0, etc * History of at least≥8 units/year of packed RBC transfusions in the prior 12 months prior to the screening period * Generally in good condition, Karnofsky performance score≥60 points for subjects≥16 years old at the time of autologous hematopoietic stem cell collection, or Lansky Play-Performance score≥60 points for subjects under 16 years old, or equivalent clinical evaluation as the investigator site's common practice Key Exclusion Criteria: * Treatment with other investigational medications or other experimental interventions 30 days prior to signing informed consent or within 6 half-lives of the drug, whichever is longer. * Subjects who have received or are receiving thalidomide and/or Luspatercept, when their drug-drug interaction on the efficacy and safety of CS-101 cannot be ruled out, unless at least there are 3 test results showing the total hemoglobin level before transfusion is below 9g/dL in the past 6 months before screening. * Previously received allogeneic hematopoietic stem cell transplantation or gene(edited) therapy. * Subjects have available related fully matching donors and are eligible and prepared for allogeneic hematopoietic stem cell transplantation. * Those with active infections, including but not limited to: HIV, hepatitis B, hepatitis C, cytom…